Table 3.
Univariate analysis of PFS.
| PFS | |||
|---|---|---|---|
| Parameters | Univariate analysis | ||
| HR (95%CI) | Median PFS in years (95% CI) | p-value | |
| Gender | |||
| ♂ | 1.3 (0.6–2.9) | 10 (3.6–16.3) | 0.432 |
| ♀ | 14 (2.8–25.2) | ||
| Age | |||
| ≤ 60 y/o | 2.5 (1.1–5.8) | 14.0 (10.2–14.8) | 0.021 |
| > 60 y/o vs | 10.0 (5.1–14.8) | ||
| Histology | |||
| FL | 1.3 (0.6–2.8) | Not reached | 0.427 |
| MZL | 11.0 (5.2–16.8) | ||
| Ann Arbor staging | |||
| St. I | 0.9 (0.6–1.5) | 11.0 (7.4–14.6) | 0.751 |
| St. II | Not reached | ||
| Extranodal | |||
| Yes | 1.2 (0.6–2.7) | 11.0 (4.5–17.5) | 0.541 |
| No | Not reached | ||
| RT as primary vs recurrent | |||
| Primary treatment | 1.9 (0.7–5.1) | 14.0 (8.3–19.7) | 0.179 |
| Recurrent treatment | 10.0 (3.8–10.0) | ||
| Total dose of RT | |||
| ≤ 36.0 Gy | 1.4 (0.6–2.9) | 14.0 (8.7–19.7) | 0.425 |
| > 36.0 Gy | 10.0 (4.9–15.1) | ||
| Technique of RT | |||
| 3D/VMAT | 0.3 (0.1–0.8) | 14.0 (8.2–19.8) | 0.059 |
| 2D | 4.0 (1.1–6.9) | ||
| Radiation field | |||
| IFRT | 1.3 (0.6–2.7) | Not reached | 0.543 |
| ISRT | 10 (4.3–15.7) | ||